Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744

• PubMed
Perkovic V, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744)| false
• Search Google Scholar
• Export Citation

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMoa1504720

• PubMed
Zinman B, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMoa1504720)| false
• Search Google Scholar
• Export Citation

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347–357. doi: 10.1056/NEJMoa1812389

• PubMed
Wiviott SD, Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347–357. doi: 10.1056/NEJMoa1812389)| false
• Search Google Scholar
• Export Citation

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657. doi: 10.1056/NEJMc1712572

• PubMed
Neal B, Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657. doi: 10.1056/NEJMc1712572)| false
• Search Google Scholar
• Export Citation

Pham PT, et al. Diabetes mellitus after solid organ transplantation. In: Endotext [Internet], edited by Feingold KR, et al. South Dartmouth, Massachusetts, MDText.com, Inc., 2000–2019 Apr 15. https://www.ncbi.nlm.nih.gov/books/NBK378977/

• PubMed
Pham PT, Diabetes mellitus after solid organ transplantation. In: Endotext [Internet], edited by Feingold KR, South Dartmouth, Massachusetts, MDText.com, Inc., 2000–2019 Apr 15. https://www.ncbi.nlm.nih.gov/books/NBK378977/)| false
• Search Google Scholar
• Export Citation

Halden TAS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:1067–1074. doi: 10.2337/dc19-0093

• PubMed
Halden TAS, Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:1067–1074. doi: 10.2337/dc19-0093)| false
• Search Google Scholar
• Export Citation

Mahling M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019; 44:984–992. doi: 10.1159/000501854

• PubMed
Mahling M, Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019; 44:984–992. doi: 10.1159/000501854)| false
• Search Google Scholar
• Export Citation

Rajasekeran H, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series. Diabetes Care 2017; 40:e75–e76. doi: 10.2337/dc17-0237

• PubMed
Rajasekeran H, Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series. Diabetes Care 2017; 40:e75–e76. doi: 10.2337/dc17-0237)| false
• Search Google Scholar
• Export Citation

AlKindi F, et al. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc 2020; 52:175–178. doi: 10.1016/j.transproceed.2019.11.007

• PubMed
AlKindi F, Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc 2020; 52:175–178. doi: 10.1016/j.transproceed.2019.11.007)| false
• Search Google Scholar
• Export Citation

Cehic MG, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct 2019; 5:e450. doi: 10.1097/TXD.0000000000000885

• PubMed
Cehic MG, Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct 2019; 5:e450. doi: 10.1097/TXD.0000000000000885)| false
• Search Google Scholar
• Export Citation

Heerspink HJL, et al. Nephrol Dial Transplant 2020; 35:274–282. doi: 10.1093/ndt/gfz290

• PubMed
Heerspink HJL, Nephrol Dial Transplant 2020; 35:274–282. doi: 10.1093/ndt/gfz290)| false
• Search Google Scholar
• Export Citation

Schwaiger E, et al. Empagliflozin in posttransplantation diabetes mellitus; a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19:907–919. doi: 10.1111/ajt.15223

• PubMed
Schwaiger E, Empagliflozin in posttransplantation diabetes mellitus; a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19:907–919. doi: 10.1111/ajt.15223)| false
• Search Google Scholar
• Export Citation

Halden TS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:1067–1074.

• PubMed
Halden TS, Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:1067–1074.)| false
• Search Google Scholar
• Export Citation

Hecking M, Jenssen T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 2019; 15:525–526.

• PubMed
Hecking M, Jenssen T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 2019; 15:525–526.)| false
• Search Google Scholar
• Export Citation